Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Human iPS cell–derived alveolar epithelium repopulates lung extracellular matrix
Mahboobe Ghaedi, Elizabeth A. Calle, Julio J. Mendez, Ashley L. Gard, Jenna Balestrini, Adam Booth, Peter F. Bove, Liqiong Gui, Eric S. White, Laura E. Niklason
Mahboobe Ghaedi, Elizabeth A. Calle, Julio J. Mendez, Ashley L. Gard, Jenna Balestrini, Adam Booth, Peter F. Bove, Liqiong Gui, Eric S. White, Laura E. Niklason
View: Text | PDF
Technical Advance Pulmonology

Human iPS cell–derived alveolar epithelium repopulates lung extracellular matrix

  • Text
  • PDF
Abstract

The use of induced pluripotent stem cells (iPSCs) has been postulated to be the most effective strategy for developing patient-specific respiratory epithelial cells, which may be valuable for lung-related cell therapy and lung tissue engineering. We generated a relatively homogeneous population of alveolar epithelial type II (AETII) and type I (AETI) cells from human iPSCs that had phenotypic properties similar to those of mature human AETII and AETI cells. We used these cells to explore whether lung tissue can be regenerated in vitro. Consistent with an AETII phenotype, we found that up to 97% of cells were positive for surfactant protein C, 95% for mucin-1, 93% for surfactant protein B, and 89% for the epithelial marker CD54. Additionally, exposing induced AETII to a Wnt/β-catenin inhibitor (IWR-1) changed the iPSC-AETII–like phenotype to a predominantly AETI-like phenotype. We found that of induced AET1 cells, more than 90% were positive for type I markers, T1α, and caveolin-1. Acellular lung matrices were prepared from whole rat or human adult lungs treated with decellularization reagents, followed by seeding these matrices with alveolar cells derived from human iPSCs. Under appropriate culture conditions, these progenitor cells adhered to and proliferated within the 3D lung tissue scaffold and displayed markers of differentiated pulmonary epithelium.

Authors

Mahboobe Ghaedi, Elizabeth A. Calle, Julio J. Mendez, Ashley L. Gard, Jenna Balestrini, Adam Booth, Peter F. Bove, Liqiong Gui, Eric S. White, Laura E. Niklason

×

Figure 3

Functional characterization of AETII cells derived from iPSCs, day 22 of differentiation (C1 clone).

Options: View larger image (or click on image) Download as PowerPoint
Functional characterization of AETII cells derived from iPSCs, day 22 of...
(A–D) Immunostaining of AETII marker: (A) pro-SPC, (B) mucin-1, (C) pro-SPA, (D) pro-SPB. Scale bar: 63 μm. (E and F) Transmission electron microscopy represents (E) human AETII and (F) iPSC-derived AETII containing characteristic cytoplasmic laminar bodies. Scale bars: 0.5 μm. (G) qRT-PCR analysis in undifferentiated iPSC, DE, AFE, and differentiated AETII cells compared with human AETII from 3 independent experiments. Values from the triplicate PCR reactions for a GOI (SPA, SPB, SPC, and mucin-1) were normalized against average GAPDH Ct values from the same cDNA sample. Fold change of GOI tra-script levels between iPS-derived AETII and human type II cells equals 2–ΔΔCt, where ΔCt = Ct(GOI) – Ct(GAPDH), and ΔΔCt = ΔCt(AETII) – ΔCt(ATII). (H) Flow cytometry analysis for the percentage of positive cells for AETII and AETI markers at day 22. Cells were negative for p63 and SOX2. (I) Expression of albumin, CD31, TSHR, and CC10 (CCSP) in iPSC-AETII. Cells were negative for genes indicative of other lineages at day 22. (J) Amount of secreted SPC in the iPSC-derived AETII supernatants collected during the time course of differentiation compared with human type II cells determined by ELISA. (K) Western blot for pro-SPC in iPSC-AETII at day 22 and β-actin as an internal control. Bars indicate ± SEM and n = 3 independent experiments for qRT-PCR, ELISA, and flow cytometry. *P < 0.05.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts